Sarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term, Sustainable Growth and Provides Update on ELEVIDYS Label – Sarepta Therapeutics
- Sarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term, Sustainable Growth and Provides Update on ELEVIDYS Label Sarepta Therapeutics
- Sarepta to cut 500 jobs after gene therapy setback TradingView
- Sarepta Therapeutics Halts ELEVIDYS Shipments for Non-Ambulatory DMD Patients Yahoo Finance
- Sarepta to cut 36% of workforce amid strategic restructuring Investing.com
- Sarepta Therapeutics makes layoffs after gene therapy setback The Business Journals